Return-Path: <linux-kernel-owner+willy=40w.ods.org-S932537AbVJECaI@vger.kernel.org>
Received: (majordomo@vger.kernel.org) by vger.kernel.org via listexpand
	id S932537AbVJECaI (ORCPT <rfc822;willy@w.ods.org>);
	Tue, 4 Oct 2005 22:30:08 -0400
Received: (majordomo@vger.kernel.org) by vger.kernel.org id S1751209AbVJECaI
	(ORCPT <rfc822;linux-kernel-outgoing>);
	Tue, 4 Oct 2005 22:30:08 -0400
Received: from oky139.okanagan.bc.ca ([142.231.70.139]:58631 "HELO moerbel.de")
	by vger.kernel.org with SMTP id S1751193AbVJECaG (ORCPT
	<rfc822;linux-kernel@vger.kernel.org>);
	Tue, 4 Oct 2005 22:30:06 -0400
Message-ID: <dfcd01c5c94b$2989258c$b112fbed@moerbel.de>
From: "Oscar Flowers" <oscarflowers_up@cies.co.kr>
To: linux-kernel@vger.kernel.org
Subject: MibcroCap Profile
Date: Wed, 05 Oct 2005 02:26:52 +0100
X-Priority: 3
X-MSMail-Priority: Normal
X-Mailer: Microsoft Outlook Express 6.00.2600.0000
X-MimeOLE: Produced By Microsoft MimeOLE V6.00.2600.0000
Mime-Version: 1.0
Content-Transfer-Encoding: 7bit
Content-Type: text/plain; charset=iso-8859-1
Sender: linux-kernel-owner@vger.kernel.org
X-Mailing-List: linux-kernel@vger.kernel.org

ATTENTION INVESTING PUBLIC

 

ASCE . PK
Recent Trading Range: $.80 - $.90
Expected Trading Range: $1.50 - $2.00
ASCE . PK

 
BELLEVUE, WA. September 14, 2005 . Ascentia Biomedical Corporation (OTC Pink Sheets; ASCE), a leading researcher and developer of efficacious 
pharmaceuticals, compounds and other products, announces it has received an initial commitment for up to $1 million in funding for continued research 
particularly in anti-cancer compounds and for organizational growth.


BELLEVUE, WA. September 27th, 2005 . Ascentia Biomedical Corporation (OTC Pink Sheets; ASCE), a leading researcher and developer of efficacious 
pharmaceuticals, compounds and other products, announces the addition of Dr. Philip Mease to its Scientific Advisory Board. Dr. James Clagett, 
President and CEO of Ascentia said, .We are privileged to have such an internationally recognized rheumatologist who has a distinguished career in the 
clinical development of therapies for rheumatic diseases.  Dr. Mease.s experience in clinical drug discovery along with his respected relationship with 
drug regulatory agencies will greatly assist Ascentia in its drug discovery and commercialization program..


Dr. Mease is Chief of the Rheumatology Clinical Research Division at Swedish Hospital, Clinical Professor at the University of Washington, and founder 
of Seattle Rheumatology Associates.  Dr. Mease graduated from Stanford University Medical School and completed his medical training at University of 
Washington, Seattle.

 
About Ascentia Biomedical Corporation

Our focus is SOLUTIONS through RESEARCH and DISCOVERY. Ascentia is developing and commercializing new pharmaceutical and biomedical products for 
application in a number of areas, including treatment for asthma, arthritis, psoriasis and cancer.  Initially, a majority of these products will be 
secured through direct purchase or through licensing. As the Company grows and evolves, more products will be developed internally. Ascentia is focused 
on therapies for cancer and diseases of inflammation.


Forward-Looking Statements

 

This release may contain forward-looking statements that involve risks

and uncertainties. These statements do not constitute representations

or promises. Rather, these statements express opinions, hopes and

desires that may not be based on objective or factual criteria or

measurable results. No one should rely on such statements for any

purpose except as specifically stated

 

To get taken off the list email NOSTK@Yahoo.com

